The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
Open accessAbstract
LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients, but still little is understood about how it is regulated or functions. In the present study we have demonstrated that 14-3-3 protein isoforms interact with LRRK2. Consistent with this, endogenous LRRK2 isolated from Swiss 3T3 cells or various mouse tissues is associated with endogenous 14-3-3 isoforms. We have established that 14-3-3 binding is mediated by phosphorylation of LRRK2 at two conserved residues (Ser910 and Ser935) located before the leucine-rich repeat domain. Our results suggests that mutation of Ser910 and/or Ser935 to disrupt 14-3-3 binding does not affect intrinsic protein kinase activity, but induces LRRK2 to accumulate within discrete cytoplasmic pools, perhaps resembling inclusion bodies. To investigate links between 14-3-3 binding and Parkinson's disease, we studied how 41 reported mutations of LRRK2 affected 14-3-3 binding and cellular localization. Strikingly, we found that five of the six most common pathogenic mutations (R1441C, R1441G, R1441H, Y1699C and I2020T) display markedly reduced phosphorylation of Ser910/Ser935 thereby disrupting interaction with 14-3-3. We have also demonstrated that Ser910/Ser935 phosphorylation and 14-3-3 binding to endogenous LRRK2 is significantly reduced in tissues of homozygous LRRK2(R1441C) knock-in mice. Consistent with 14-3-3 regulating localization, all of the common pathogenic mutations displaying reduced 14-3-3-binding accumulated within inclusion bodies. We also found that three of the 41 LRRK2 mutations analysed displayed elevated protein kinase activity (R1728H, ~2-fold; G2019S, ~3-fold; and T2031S, ~4-fold). These results provide the first evidence suggesting that 14-3-3 regulates LRRK2 and that disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity
Yaffe, M. B., Rittinger, K., Volinia, S., Caron, P. R., Aitken, A., Leffers, H., Gamblin, S. J., Smerdon, S. J., & Cantley, L. C. (1997) · Cell · doi:10.1016/s0092-8674(00)80487-0 · Cited by 1,604
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228
Physiological and Biochemical Aspects of Nervous Integration
Carlson, F. D. (1968) · Cited by 749
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671
14-3-3 proteins in the nervous system
Berg, D., Holzmann, C., & Riess, O. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1197 · Cited by 616
α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins
Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., & Wolozin, B. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-14-05782.1999 · Cited by 564
Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes
MACKINTOSH, C. (2004) · Biochemical Journal · doi:10.1042/bj20031332 · Cited by 526
LRRK2 in Parkinson's disease: protein domains and functional insights
Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P., & Gallo, K. A. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.03.006 · Cited by 489
Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070209 · Cited by 472
Self-citationAlegre-Abarrategui, J., Christian, H., Lufino, M. M. P., Mutihac, R., Venda, L. L., Ansorge, O., & Wade-Martins, R. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp346 · Cited by 432
Smith, W. W., Pei, Z., Jiang, H., Moore, D. J., Liang, Y., West, A. B., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508052102 · Cited by 424
Chen, H.-K., Fernandez-Funez, P., Acevedo, S. F., Lam, Y. C., Kaytor, M. D., Fernandez, M. H., Aitken, A., Skoulakis, E. M. C., Orr, H. T., Botas, J., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00349-0 · Cited by 414
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice
Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E. N., & Shen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906334106 · Cited by 304
Self-citationPhosphorylation‐dependent interactions between enzymes of plant metabolism and 14‐3‐3 proteins
Moorhead, G., Douglas, P., Cotelle, V., Harthill, J., Morrice, N., Meek, S., Deiting, U., Stitt, M., Scarabel, M., Aitken, A., et al. (1999) · The Plant Journal · doi:10.1046/j.1365-313x.1999.00417.x · Cited by 281
Self-citationReed, S. E., Staley, E. M., Mayginnes, J. P., Pintel, D. J., & Tullis, G. E. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.07.024 · Cited by 251
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
Nichols, R. J., Dzamko, N., Hutti, J. E., Cantley, L. C., Deak, M., Moran, J., Bamborough, P., Reith, A. D., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20091035 · Cited by 197
Self-citationWang, L., Xie, C., Greggio, E., Parisiadou, L., Shim, H., Sun, L., Chandran, J., Lin, X., Lai, C., Yang, W.-J., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0185-08.2008 · Cited by 188
The Parkinson’s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites
Greggio, E., Taymans, J., Zhen, Y., Ryder, J. W., Vancraenenbroeck, R., Beilina, A. G., Sun, P., Deng, J., Jaffe, H., Baekelandt, V., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.163 · Cited by 159
Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease
Yacoubian, T. A., Slone, S. R., Harrington, A. J., Hamamichi, S., Schieltz, J. M., Caldwell, K. A., Caldwell, G. A., & Standaert, D. G. (2010) · Cell Death and Disease · doi:10.1038/cddis.2009.4 · Cited by 143
14‐3‐3η is a novel regulator of parkin ubiquitin ligase
Sato, S., Chiba, T., Sakata, E., Kato, K., Mizuno, Y., Hattori, N., & Tanaka, K. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600774 · Cited by 138
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease
Biskup, S., & West, A. B. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.015 · Cited by 115
Paisán‐Ruiz, C., Nath, P., Washecka, N., Gibbs, J. R., & Singleton, A. (2008) · Human Mutation · doi:10.1002/humu.20668 · Cited by 108
Haußer, A., Link, G., Hoene, M., Russo, C., Selchow, O., & Pfizenmaier, K. (2006) · Journal of Cell Science · doi:10.1242/jcs.03104 · Cited by 98
Regulation of the polarity kinases PAR-1/MARK by 14-3-3 interaction and phosphorylation
Göransson, O., Deák, M., Wullschleger, S., MORRICE, N. A., Prescott, A. R., & Alessi, D. R. (2006) · Journal of Cell Science · doi:10.1242/jcs.03097 · Cited by 75
Self-citationDubois, F., Vandermoere, F., Gernez, A., Murphy, J. E., Toth, R. L., Chen, S., Geraghty, K. M., MORRICE, N. A., & MacKintosh, C. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800544-mcp200 · Cited by 71
Self-citationLRRK2 in Parkinson’s disease: biochemical functions
Anand, V. S., & Braithwaite, S. P. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07341.x · Cited by 67
Li, X., Moore, D. J., Xiong, Y., Dawson, T. M., & Dawson, V. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127639 · Cited by 64
Ubl, A., Berg, D., Holzmann, C., et al. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00510-7 · Cited by 63
Cited by
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. (2016) · eLife · doi:10.7554/elife.12813 · Cited by 1,042
Self-citationThe role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. R. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2935 · Cited by 539
Steger, M., Diez, F., Dhekne, H. S., Lis, P., Nirujogi, R. S., Karayel, O., Tonelli, F., Martinez, T. N., Lorentzen, E., Pfeffer, S. R., et al. (2017) · eLife · doi:10.7554/elife.31012 · Cited by 482
Self-citationGenetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448
“The flanking ankryn, leucine rich repeat andWD40 domains allow for interaction with numerous other proteins including 14-3-3, BAG5, GAK, and Rab7l1 (Nichols et al. 2010; MacLeod et al. 2013; Beilina et al. 2014).”
BackgroundRecent Advances in the Genetics of Parkinson's Disease
Martin, I., Dawson, V. L., & Dawson, T. M. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101440 · Cited by 437
Metadata
- Authors
- Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R., & Alessi, D. R.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2010-08-27
- Volume
- 430
- Issue
- 3
- Pages
- 393-404
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W1977391806
- Cited by
- 386
- References
- 32
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.